These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Warmuth M; Danhauser-Riedl S; Hallek M Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019 [TBL] [Abstract][Full Text] [Related]
4. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597 [TBL] [Abstract][Full Text] [Related]
6. The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome. Westbrook CA Cancer; 1992 Sep; 70(6 Suppl):1695-700. PubMed ID: 1516023 [TBL] [Abstract][Full Text] [Related]
7. [Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]. Huang W; Cao Q; Lu Y Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):662-5, 708. PubMed ID: 7866899 [TBL] [Abstract][Full Text] [Related]
12. Phosphorylation substrates and altered signalling in leukemias caused by BCR/ABL. Groffen J; de Jong R; Haataja L; Kaartinen V; Heisterkamp N Leukemia; 1999 Apr; 13 Suppl 1():S81-2. PubMed ID: 10232372 [No Abstract] [Full Text] [Related]
13. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454 [TBL] [Abstract][Full Text] [Related]
14. Clinical use of the bcr/abl probe test in the evaluation of chronic myeloid leukemia patients. Yazici H; Sengün Z; Aktan M; Aktuglu G; Uskent N; Dalay N J Exp Clin Cancer Res; 1997 Mar; 16(1):105-9. PubMed ID: 9148870 [TBL] [Abstract][Full Text] [Related]
15. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia. Vaerman JL; Lewalle P; Martiat P Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481 [TBL] [Abstract][Full Text] [Related]
16. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. Tauchi T; Miyazawa K; Ohyashiki K; Toyama K Hum Cell; 1996 Dec; 9(4):333-6. PubMed ID: 9183666 [TBL] [Abstract][Full Text] [Related]
17. Detection of bcr/c-abl mRNA in chronic myelogenous leukemia by polymerase chain reaction to identify chromosome translocation. Lin CP; Chen PM; Yen JS; Wang RL; Lee LS; Chen PH; Chang JG J Formos Med Assoc; 1992 Mar; 91(3):247-51. PubMed ID: 1354683 [TBL] [Abstract][Full Text] [Related]
18. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia. Kohler S; Galili N; Sklar JL; Donlon TA; Blume KG; Cleary ML Leukemia; 1990 Aug; 4(8):541-7. PubMed ID: 2201832 [TBL] [Abstract][Full Text] [Related]
19. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Sawyers CL Leuk Lymphoma; 1993; 11 Suppl 2():101-3. PubMed ID: 8124222 [TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia. Blennerhassett GT; Furth ME; Anderson A; Burns JP; Chaganti RS; Blick M; Talpaz M; Dev VG; Chan LC; Wiedemann LM Leukemia; 1988 Oct; 2(10):648-57. PubMed ID: 3050293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]